The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning

Cancer Treatment Reviews

Volumn 32, Issue 4, 2006, Pages 245-260

  van Baardwijk, Angela ^a,b   Baumert, Brigitta G ^b   Bosmans, Geert ^b   van Kroonenburgh, Marinus ^b   Stroobants, Sigrid ^c   Gregoire, Vincent ^d   Lambin, Philippe ^a,b   De Ruysscher, Dirk ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Planning; Positron emission tomography; Primary tumour; Radiation; Radiotherapy; Regional lymph nodes; Target volume delineation; Treatment

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GADOLINIUM; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BRACHYTHERAPY; BRAIN TUMOR; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; ESOPHAGUS CANCER; FEMALE GENITAL TRACT TUMOR; HEAD AND NECK TUMOR; HISTOPATHOLOGY; HUMAN; INFORMATION RETRIEVAL; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; LUNG CANCER; LYMPH NODE METASTASIS; LYMPHOMA; MEDLINE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVER VARIATION; POSITRON EMISSION TOMOGRAPHY; PREDICTION; RADIATION DOSE; RADIATION INJURY; SENSITIVITY AND SPECIFICITY; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR VOLUME; LYMPH NODE; METHODOLOGY; NEOPLASM; PATIENT CARE PLANNING; REVIEW; SCINTISCANNING;

FLUORODEOXYGLUCOSE F18; HUMANS; LYMPH NODES; NEOPLASM STAGING; NEOPLASMS; PATIENT CARE PLANNING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 33745535722     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2006.02.002     Document Type: Article

References (144)

1. Phelps M.E. Inaugural article: positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci USA 97 (2000) 9226-9233
2. Kantorova I., Lipska L., Belohlavek O., et al. Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making. J Nucl Med 44 (2003) 1784-1788
3. Follen M., Levenback C.F., Iyer R.B., et al. Imaging in cervical cancer. Cancer 98 (2003) 2028-2038
4. Rasanen J.V., Sihvo E.I., Knuuti M.J., et al. Prospective analysis of accuracy of positron emission tomography, computed tomography, and endoscopic ultrasonography in staging of adenocarcinoma of the esophagus and the esophagogastric junction. Ann Surg Oncol 10 (2003) 954-960
5. Young C.S., Young B.L., and Smith S.M. Staging Hodgkin's disease with 18-FDG PET. Comparison with CT and surgery. Clin Positron Imag 1 (1998) 161-164
6. Antoch G., Stattaus J., Nemat A.T., et al. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology 229 (2003) 526-533
7. Luketich J.D., Friedman D.M., Meltzer C.C., et al. The role of positron emission tomography in evaluating mediastinal lymph node metastases in non-small-cell lung cancer. Clin Lung Cancer 2 (2001) 229-233
8. Antoch G., Vogt F.M., Freudenberg L.S., et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. Jama 290 (2003) 3199-3206
9. Antoch G., Saoudi N., Kuehl H., et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-d-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 22 (2004) 4357-4368
10. Kresnik E., Mikosch P., Gallowitsch H.J., et al. Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods. Eur J Nucl Med 28 (2001) 816-821
11. Greven K.M., Williams III D.W., McGuirt Sr. W.F., et al. Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck 23 (2001) 942-946
12. Halfpenny W., Hain S.F., Biassoni L., et al. FDG-PET. A possible prognostic factor in head and neck cancer. Br J Cancer 86 (2002) 512-516
13. Rege S., Safa A.A., Chaiken L., et al. Positron emission tomography: an independent indicator of radiocurability in head and neck carcinomas. Am J Clin Oncol 23 (2000) 164-169
14. Allal A.S., Dulguerov P., Allaoua M., et al. Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-d-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol 20 (2002) 1398-1404
15. Ahuja V., Coleman R.E., Herndon J., et al. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with non-small cell lung carcinoma. Cancer 83 (1998) 918-924
16. Allal A.S., Slosman D.O., Kebdani T., et al. Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-d-glucose. Int J Radiat Oncol Biol Phys 59 (2004) 1295-1300
17. Borst G.R., Belderbos J.S., Boellaard R., et al. Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur J Cancer 41 (2005) 1533-1541
18. Brun E., Kjellen E., Tennvall J., et al. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck 24 (2002) 127-135
19. Dhital K., Saunders C.A., Seed P.T., et al. [(18)F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur J Cardiothorac Surg 18 (2000) 425-428
20. Downey R.J., Akhurst T., Gonen M., et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 22 (2004) 3255-3260
21. Higashi K., Ueda Y., Arisaka Y., et al. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med 43 (2002) 39-45
22. Jeong H.J., Min J.J., Park J.M., et al. Determination of the prognostic value of [(18)F] fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl Med Commun 23 (2002) 865-870
23. Vansteenkiste J.F., Stroobants S.G., Dupont P.J., et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 17 (1999) 3201-3206
24. Sasaki R., Komaki R., Macapinlac H., et al. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 23 (2005) 1136-1143
25. Erdi Y.E., Macapinlac H., Rosenzweig K.E., et al. Use of PET to monitor the response of lung cancer to radiation treatment. Eur J Nucl Med 27 (2000) 861-866
26. Kitagawa Y., Nishizawa S., Sano K., et al. Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma. J Nucl Med 44 (2003) 198-206
27. Koike I., Ohmura M., Hata M., et al. FDG-PET scanning after radiation can predict tumor regrowth three months later. Int J Radiat Oncol Biol Phys 57 (2003) 1231-1238
28. Kunkel M., Forster G.J., Reichert T.E., et al. Radiation response non-invasively imaged by [18F]FDG-PET predicts local tumor control and survival in advanced oral squamous cell carcinoma. Oral Oncol 39 (2003) 170-177
29. Mac Manus M.P., Hicks R.J., Matthews J.P., et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 21 (2003) 1285-1292
30. Porceddu S.V., Jarmolowski E., Hicks R.J., et al. Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer. Head Neck 27 (2005) 175-181
31. Rogers J.W., Greven K.M., McGuirt W.F., et al. Can post-RT neck dissection be omitted for patients with head-and-neck cancer who have a negative PET scan after definitive radiation therapy?. Int J Radiat Oncol Biol Phys 58 (2004) 694-697
32. Yao M., Graham M.M., Hoffman H.T., et al. The role of post-radiation therapy FDG PET in prediction of necessity for post-radiation therapy neck dissection in locally advanced head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 59 (2004) 1001-1010
33. Brink I., Schumacher T., Mix M., et al. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imag 31 (2004) 1614-1620
34. Mah K., Caldwell C.B., Ung Y.C., et al. The impact of (18)FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: a prospective study. Int J Radiat Oncol Biol Phys 52 (2002) 339-350
35. Ciernik I.F., Dizendorf E., Baumert B.G., et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys 57 (2003) 853-863
36. Dizendorf E.V., Baumert B.G., von Schulthess G.K., et al. Impact of whole-body 18F-FDG PET on staging and managing patients for radiation therapy. J Nucl Med 44 (2003) 24-29
37. Kalff V., Hicks R.J., MacManus M.P., et al. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. J Clin Oncol 19 (2001) 111-118
38. Bujenovic S. The role of positron emission tomography in radiation treatment planning. Semin Nucl Med 34 (2004) 293-299
39. Caldwell C.B., Mah K., Ung Y.C., et al. Observer variation in contouring gross tumor volume in patients with poorly defined non-small-cell lung tumors on CT: the impact of 18FDG-hybrid PET fusion. Int J Radiat Oncol Biol Phys 51 (2001) 923-931
40. Tralins K.S., Douglas J.G., Stelzer K.J., et al. Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation. J Nucl Med 43 (2002) 1667-1673
41. Campbell M.J. Propability and decision making. Medical statistics: a commonsense approach. 3rd ed. (2002), Wiley, Chichester (UK) 38-39
42. Abdel-Nabi H., Doerr R.J., Lamonica D.M., et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 206 (1998) 755-760
43. Adams S., Baum R.P., Stuckensen T., et al. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 25 (1998) 1255-1260
44. Benchaou M., Lehmann W., Slosman D.O., et al. The role of FDG-PET in the preoperative assessment of N-staging in head and neck cancer. Acta Otolaryngol 116 (1996) 332-335
45. Dwamena B.A., Sonnad S.S., Angobaldo J.O., et al. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s-meta-analytic comparison of PET and CT. Radiology 213 (1999) 530-536
46. Eubank W.B., and Mankoff D.A. Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med 35 (2005) 84-99
47. Fischer B.M., Mortensen J., and Hojgaard L. Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review. Lancet Oncol 2 (2001) 659-666
48. Flamen P., Lerut T., Haustermans K., et al. Position of positron emission tomography and other imaging diagnostic modalities in esophageal cancer. Q J Nucl Med Mol Imag 48 (2004) 96-108
49. Gambhir S.S., Czernin J., Schwimmer J., et al. A tabulated summary of the FDG PET literature. J Nucl Med 42 (2001) 1S-93S
50. Gould M.K., Kuschner W.G., Rydzak C.E., et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med 139 (2003) 879-892
51. Hannah A., Scott A.M., Tochon-Danguy H., et al. Evaluation of 18 F-fluorodeoxyglucose positron emission tomography and computed tomography with histopathologic correlation in the initial staging of head and neck cancer. Ann Surg 236 (2002) 208-217
52. Havrilesky L.J., Kulasingam S.L., Matchar D.B., et al. FDG-PET for management of cervical and ovarian cancer. Gynecol Oncol 97 (2005) 183-191
53. Kau R.J., Alexiou C., Laubenbacher C., et al. Lymph node detection of head and neck squamous cell carcinomas by positron emission tomography with fluorodeoxyglucose F 18 in a routine clinical setting. Arch Otolaryngol Head Neck Surg 125 (1999) 1322-1328
54. Kramer H., and Groen H.J. Current concepts in the mediastinal lymph node staging of nonsmall cell lung cancer. Ann Surg 238 (2003) 180-188
55. Quon A., and Gambhir S.S. FDG-PET and beyond: molecular breast cancer imaging. J Clin Oncol 23 (2005) 1664-1673
56. Rohren E.M., Turkington T.G., and Coleman R.E. Clinical applications of PET in oncology. Radiology 231 (2004) 305-332
57. Schiepers C., Filmont J.E., and Czernin J. PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imag 30 Suppl. 1 (2003) S82-S88
58. Shvarts O., Han K.R., Seltzer M., et al. Positron emission tomography in urologic oncology. Cancer Control 9 (2002) 335-342
59. Sigg M.B., Steinert H., Gratz K., et al. Staging of head and neck tumors: [18F]fluorodeoxyglucose positron emission tomography compared with physical examination and conventional imaging modalities. J Oral Maxillofac Surg 61 (2003) 1022-1029
60. Stokkel M.P., ten Broek F.W., Hordijk G.J., et al. Preoperative evaluation of patients with primary head and neck cancer using dual-head 18fluorodeoxyglucose positron emission tomography. Ann Surg 231 (2000) 229-234
61. Stuckensen T., Kovacs A.F., Adams S., et al. Staging of the neck in patients with oral cavity squamous cell carcinomas: a prospective comparison of PET, ultrasound, CT and MRI. J Craniomaxillofac Surg 28 (2000) 319-324
62. van Westreenen H.L., Westerterp M., Bossuyt P.M., et al. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol 22 (2004) 3805-3812
63. Yau Y.Y., Samman N., and Yeung R.W. Positron emission tomography/computed tomography true fusion imaging in clinical head and neck oncology: early experience. J Oral Maxillofac Surg 63 (2005) 479-486
64. Schwartz D.L., Ford E., Rajendran J., et al. FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 61 (2005) 129-136
65. Flamen P. Positron emission tomography in gastric and esophageal cancer. Curr Opin Oncol 16 (2004) 359-363
66. Schoder H., Yeung H.W., Gonen M., et al. Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology 231 (2004) 65-72
67. Ng S.H., Yen T.C., Liao C.T., et al. 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation. J Nucl Med 46 (2005) 1136-1143
68. Gregoire V. Is there any future in radiotherapy planning without the use of PET: unraveling the myth. Radiother Oncol 73 (2004) 261-263
69. Daisne J.F., Duprez T., Weynand B., et al. Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology 233 (2004) 93-100
70. Court L.E., Dong L., Taylor N., et al. Evaluation of a contour-alignment technique for CT-guided prostate radiotherapy: an intra- and interobserver study. Int J Radiat Oncol Biol Phys 59 (2004) 412-418
71. Valicenti R.K., Sweet J.W., Hauck W.W., et al. Variation of clinical target volume definition in three-dimensional conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 44 (1999) 931-935
72. Logue J.P., Sharrock C.L., Cowan R.A., et al. Clinical variability of target volume description in conformal radiotherapy planning. Int J Radiat Oncol Biol Phys 41 (1998) 929-931
73. Weltens C., Menten J., Feron M., et al. Interobserver variations in gross tumor volume delineation of brain tumors on computed tomography and impact of magnetic resonance imaging. Radiother Oncol 60 (2001) 49-59
74. Ashamalla H., Rafla S., Parikh K., et al. The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer. Int J Radiat Oncol Biol Phys 63 (2005) 1016-1023
75. Fox J.L., Rengan R., O'Meara W., et al. Does registration of PET and planning CT images decrease interobserver and intraobserver variation in delineating tumor volumes for non-small-cell lung cancer?. Int J Radiat Oncol Biol Phys 62 (2005) 70-75
76. Van Laere K., Ceyssens S., Van Calenbergh F., et al. Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imag 32 (2005) 39-51
77. Black Q.C., Grills I.S., Kestin L.L., et al. Defining a radiotherapy target with positron emission tomography. Int J Radiat Oncol Biol Phys 60 (2004) 1272-1282
78. Bradley J.D., Dehdashti F., Mintun M.A., et al. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol 22 (2004) 3248-3254
79. Ciernik I.F., Huser M., Burger C., et al. Automated functional image-guided radiation treatment planning for rectal cancer. Int J Radiat Oncol Biol Phys 62 (2005) 893-900
80. Daisne J.F., Sibomana M., Bol A., et al. Tri-dimensional automatic segmentation of PET volumes based on measured source-to-background ratios: influence of reconstruction algorithms. Radiother Oncol 69 (2003) 247-250
81. Erdi Y.E., Mawlawi O., Larson S.M., et al. Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer 80 (1997) 2505-2509
82. Paulino A.C., and Johnstone P.A. FDG-PET in radiotherapy treatment planning: Pandora's box?. Int J Radiat Oncol Biol Phys 59 (2004) 4-5
83. Nestle U., Kremp S., Schaefer-Schuler A., et al. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer. J Nucl Med 46 (2005) 1342-1348
84. Thie J.A. Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med 45 (2004) 1431-1434
85. Boellaard R., Krak N.C., Hoekstra O.S., et al. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med 45 (2004) 1519-1527
86. Erdi Y.E., Nehmeh S.A., Pan T., et al. The CT motion quantitation of lung lesions and its impact on PET-measured SUVs. J Nucl Med 45 (2004) 1287-1292
87. Hoekstra C.J., Paglianiti I., Hoekstra O.S., et al. Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-d-glucose and positron emission tomography: an overview of different analytical methods. Eur J Nucl Med 27 (2000) 731-743
88. Heron D.E., Andrade R.S., Flickinger J., et al. Hybrid PET-CT simulation for radiation treatment planning in head-and-neck cancers: a brief technical report. Int J Radiat Oncol Biol Phys 60 (2004) 1419-1424
89. Koshy M., Paulino A.C., Howell R., et al. F-18 FDG PET-CT fusion in radiotherapy treatment planning for head and neck cancer. Head Neck 27 (2005) 494-502
90. Nishioka T., Shiga T., Shirato H., et al. Image fusion between 18FDG-PET and MRI/CT for radiotherapy planning of oropharyngeal and nasopharyngeal carcinomas. Int J Radiat Oncol Biol Phys 53 (2002) 1051-1057
91. Scarfone C., Lavely W.C., Cmelak A.J., et al. Prospective feasibility trial of radiotherapy target definition for head and neck cancer using 3-dimensional PET and CT imaging. J Nucl Med 45 (2004) 543-552
92. van Baardwijk A. Comparison of clinical target volume in PET-CT and CT-scan based treatment planning in patients in patients with head and neck cancer. ESTRO 23, October 2004; 2004. p. S177.
93. Paulino A.C., Koshy M., Howell R., et al. Comparison of CT- and FDG-PET-defined gross tumor volume in intensity-modulated radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 61 (2005) 1385-1392
94. Shah J.P. Patterns of cervical lymph node metastasis from squamous carcinomas of the upper aerodigestive tract. Am J Surg 160 (1990) 405-409
95. Kracht L.W., Miletic H., Busch S., et al. Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res 10 (2004) 7163-7170
96. Solberg T.D., Agazaryan N., Goss B.W., et al. A feasibility study of 18F-fluorodeoxyglucose positron emission tomography targeting and simultaneous integrated boost for intensity-modulated radiosurgery and radiotherapy. J Neurosurg 101 Suppl 3 (2004) 381-389
97. Gross M.W., Weber W.A., Feldmann H.J., et al. The value of F-18-fluorodeoxyglucose PET for the 3-D radiation treatment planning of malignant gliomas. Int J Radiat Oncol Biol Phys 41 (1998) 989-995
98. Nuutinen J., Sonninen P., Lehikoinen P., et al. Radiotherapy treatment planning and long-term follow-up with [(11)C]methionine PET in patients with low-grade astrocytoma. Int J Radiat Oncol Biol Phys 48 (2000) 43-52
99. Levivier M., Massager N., Wikler D., et al. Use of stereotactic PET images in dosimetry planning of radiosurgery for brain tumors: clinical experience and proposed classification. J Nucl Med 45 (2004) 1146-1154
100. Kelly P.J., Daumas-Duport C., Scheithauer B.W., et al. Stereotactic histologic correlations of computed tomography- and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms. Mayo Clin Proc 62 (1987) 450-459
101. Burger P.C., Heinz E.R., Shibata T., et al. Topographic anatomy and CT correlations in the untreated glioblastoma multiforme. J Neurosurg 68 (1988) 698-704
102. Hochberg F.H., and Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 30 (1980) 907-911
103. Oppitz U., Maessen D., Zunterer H., et al. 3D-recurrence-patterns of glioblastomas after CT-planned postoperative irradiation. Radiother Oncol 53 (1999) 53-57
104. Delbeke D., Meyerowitz C., Lapidus R.L., et al. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology 195 (1995) 47-52
105. Vansteenkiste J.F. Nodules, CT-scans and PET-scans: a good partnership. Lung Cancer 45 (2004) 29-30
106. Bradley J., Thorstad W.L., Mutic S., et al. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 59 (2004) 78-86
107. Nestle U., Walter K., Schmidt S., et al. 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. Int J Radiat Oncol Biol Phys 44 (1999) 593-597
108. Erdi Y.E., Rosenzweig K., Erdi A.K., et al. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol 62 (2002) 51-60
109. Mac Manus M.P., and Hicks R.J. PET scanning in lung cancer: current status and future directions. Semin Surg Oncol 21 (2003) 149-155
110. Munley M.T., Marks L.B., Scarfone C., et al. Multimodality nuclear medicine imaging in three-dimensional radiation treatment planning for lung cancer: challenges and prospects. Lung Cancer 23 (1999) 105-114
111. Vanuytsel L.J., Vansteenkiste J.F., Stroobants S.G., et al. The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol 55 (2000) 317-324
112. Kamel E.M., Zwahlen D., Wyss M.T., et al. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer. J Nucl Med 44 (2003) 1911-1917
113. Birim O., Kappetein A.P., Stijnen T., et al. Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer. Ann Thorac Surg 79 (2005) 375-382
114. Kiffer J.D., Berlangieri S.U., Scott A.M., et al. The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer. Lung Cancer 19 (1998) 167-177
115. Giraud P., Grahek D., Montravers F., et al. CT and (18)F-deoxyglucose (FDG) image fusion for optimization of conformal radiotherapy of lung cancers. Int J Radiat Oncol Biol Phys 49 (2001) 1249-1257
116. Nestle U., Hellwig D., Schmidt S., et al. 2-Deoxy-2-[18F]fluoro-d-glucose positron emission tomography in target volume definition for radiotherapy of patients with non-small-cell lung cancer. Mol Imag Biol 4 (2002) 257-263
117. Senan S., Burgers S., Samson M.J., et al. Can elective nodal irradiation be omitted in stage III non-small-cell lung cancer? Analysis of recurrences in a phase II study of induction chemotherapy and involved-field radiotherapy. Int J Radiat Oncol Biol Phys 54 (2002) 999-1006
118. Sorensen P.H.O. The location of recurrences in patients with non-small lung cancer treated with involved-field irradiation [Abstract]. Lung Cancer (2000) S171
119. van Der Wel A., Nijsten S., Hochstenbag M., et al. Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study. Int J Radiat Oncol Biol Phys 61 (2005) 649-655
120. De Ruysscher D., Wanders S., van Haren E., et al. Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys 62 (2005) 988-994
121. Giraud P., Antoine M., Larrouy A., et al. Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning. Int J Radiat Oncol Biol Phys 48 (2000) 1015-1024
122. Vrieze O., Haustermans K., De Wever W., et al. Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma?. Radiother Oncol 73 (2004) 269-275
123. Leong T.E.C., and Yuen K. A prospective study to evaluate the impact of coregistered PET/CT images on radiotherapy treatment planning for esophageal cancer [Abstract ASTRO 2004]. Int J Radiat Oncol Biol Phys 60 (2004) S139-S140
124. Mutic S., Grigsby P.W., Low D.A., et al. PET-guided three-dimensional treatment planning of intracavitary gynecologic implants. Int J Radiat Oncol Biol Phys 52 (2002) 1104-1110
125. Malyapa R.S., Mutic S., Low D.A., et al. Physiologic FDG-PET three-dimensional brachytherapy treatment planning for cervical cancer. Int J Radiat Oncol Biol Phys 54 (2002) 1140-1146
126. Tsai C.S., Chang T.C., Lai C.H., et al. Preliminary report of using FDG-PET to detect extrapelvic lesions in cervical cancer patients with enlarged pelvic lymph nodes on MRI/CT. Int J Radiat Oncol Biol Phys 58 (2004) 1506-1512
127. Esthappan J., Mutic S., Malyapa R.S., et al. Treatment planning guidelines regarding the use of CT/PET-guided IMRT for cervical carcinoma with positive paraaortic lymph nodes. Int J Radiat Oncol Biol Phys 58 (2004) 1289-1297
128. Lee Y.K., Cook G., Flower M.A., et al. Addition of 18F-FDG-PET scans to radiotherapy planning of thoracic lymphoma. Radiother Oncol 73 (2004) 277-283
129. Hutchings M., Eigtved A.I., and Specht L. FDG-PET in the clinical management of Hodgkin lymphoma. Crit Rev Oncol Hematol 52 (2004) 19-32
130. Lammering G. DRD, de Haas D, et al. First Report on the use of a dedicated combined PET-CT simulator in rectal cancer patients. ESTRO 23, 2004; 2004. p. S445.
131. Bastiaannet E., Groen H., Jager P.L., et al. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev 30 (2004) 83-101
132. Delbeke D., and Pinson C.W. Pancreatic tumors: role of imaging in the diagnosis, staging, and treatment. J Hepatobiliary Pancreat Surg 11 (2004) 4-10
133. Israel-Mardirosian N., and Adler L.P. Positron emission tomography of soft tissue sarcomas. Curr Opin Oncol 15 (2003) 327-330
134. Jadvar H., and Fischman A.J. Evaluation of rare tumors with [F-18]Fluorodeoxyglucose positron emission tomography. Clin Positron Imag 2 (1999) 153-158
135. Kumar R., and Alavi A. Clinical applications of fluorodeoxyglucose-positron emission tomography in the management of malignant melanoma. Curr Opin Oncol 17 (2005) 154-159
136. Pacak K., Eisenhofer G., and Goldstein D.S. Functional imaging of endocrine tumors: role of positron emission tomography. Endocr Rev 25 (2004) 568-580
137. Hudson M.M., Krasin M.J., and Kaste S.C. PET imaging in pediatric Hodgkin's lymphoma. Pediatr Radiol 34 (2004) 190-198
138. Jadvar H., Alavi A., Mavi A., et al. PET in pediatric diseases. Radiol Clin North Am 43 (2005) 135-152
139. Shulkin B.L. PET applications in pediatrics. Q J Nucl Med 41 (1997) 281-291
140. Krasin M.J., Hudson M.M., and Kaste S.C. Positron emission tomography in pediatric radiation oncology: integration in the treatment-planning process. Pediatr Radiol 34 (2004) 214-221
141. Swift P. Novel techniques in the delivery of radiation in pediatric oncology. Pediatr Clin North Am 49 (2002) 1107-1129
142. Angelakis P VJ, Kollias G, Paraskevopoulou C, Damatopoulou A. Lymphomas and 3D conformal radiotherapy. In: ASCO annual meeting; 2005.
143. De Ruysscher D., Wanders S., Minken A., et al. Effects of radiotherapy planning with a dedicated combined PET-CT-simulator of patients with non-small cell lung cancer on dose limiting normal tissues and radiation dose-escalation: a planning study. Radiother Oncol 77 (2005) 5-10
144. Mutic S., Malyapa R.S., Grigsby P.W., et al. PET-guided IMRT for cervical carcinoma with positive para-aortic lymph nodes-a dose-escalation treatment planning study. Int J Radiat Oncol Biol Phys 55 (2003) 28-35